课题基金 / 基金详情

Role of antigen-specific T cell responses in the control of TB

Role of antigen-specific T cell responses in the control of TB
抗原特异性 T 细胞反应在结核病控制中的作用
批准号:
8693152
负责人:
HENRY M BLUMBERG
金额:
$270.49万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-11 至 2021-07-31

项目摘要

项目成果

HENRY M BLUMBERG的其他基金

相似基金

相关文献

中文摘要
翻译
总体U19申请的描述(由申请人提供):我们的TBRU专注于对M.在一个实施方案中,本发明涉及一种用于检测结核病(Mtb)的潜伏性TB感染(LTBI)的方法,以检验以下总体假设:潜伏性TB感染(LTBI)作为细菌和免疫状态的谱存在,至少三种免疫状态可以被区分并对应于:1)过去的但清除的Mtb感染; 2)具有进展为活动性疾病的低风险的稳定的LTBI;或3)具有进展为活动性TB疾病的高风险的LTBI。为了验证这一假设,我们将确定T细胞特征,包括识别的抗原的宽度,表型,以及Mtb特异性CD 4和CDB T细胞的功能,与人类和实验感染的非人灵长类动物中独特的前瞻性研究中确定的结果相关。除了独特的前瞻性研究外,我们将使用一种新的“反应谱测定”(RSA),其中包括>60种战略选择的Mtb抗原和表位肽,以测定具有不同风险和进展为活动性TB的速率的LTBI受试者中抗原识别的定量宽度和特异性模式。此外,RSA中鉴定的抗原和表位将用于设计HLA-肽四聚体,用于Mtb表位特异性T细胞的表型和功能能力的高分辨率研究。这些研究的结果采用了包括质谱细胞术(CyTOF)在内的先进技术,与RSA的结果一起,将用于识别LTBI不同风险类别的T细胞特征。某些经过验证的T细胞特征将对应于有效的免疫反应,这些免疫反应是结核病疫苗开发的理想目标,而其他T细胞特征将有助于识别进展为活动性结核病风险最高的LTBI个体,因此可以优先考虑这些个体进行预防性干预。我们的人类研究将在美国佐治亚州亚特兰大市进行,并与肯尼亚医学研究所/美国疾病控制中心(KEMRI/CDC)的研究人员合作;非人灵长类动物的结核病研究将由两个国家灵长类动物研究中心(Yerkes和Tulane)的专家进行。我们组建的团队拥有广泛的知识和专业知识,并准备提高对结核病免疫力的认识,以促进消除结核病。
英文摘要
DESCRIPTION OF THE OVERALL U19 APPLICATION (provided by applicant): Our TBRU focuses on immunity to M. tuberculosis (Mtb), to test the overall hypothesis that latent TB infection (LTBI) exists as a spectrum of bacterial and immunologic states, that at least three immunological states can be distinguished and correspond to: 1) past, but cleared Mtb infection; 2] stable LTBI with a low risk of progression to active disease; or 3) LTBI with a high risk of progression to active TB disease. To test this hypothesis, we will identify T cell signatures, consisting of the breadth of antigens recognized, the phenotypes, and the functions of Mtb-specific CD4 and CDB T cells, with correlations to outcomes determined in unique prospective studies in humans and in experimentally-infected nonhuman primates. In addition to unique prospective studies, we will use a novel 'Response Spectrum Assay' (RSA) that includes >60 strategically-selected Mtb antigens and epitope peptides, to assay the quantitative breadth and specific pattern of antigen recognition in LTBI subjects with distinct risks and rates of progression to active TB. In addition, antigens and epitopes identified in the RSA will be used to design HLA-peptide tetramers for high-resolution studies of the phenotypes and functional capabilities of Mtb epitope-specific T cells. The results of these studies, which employ advanced technologies including mass cytometry (CyTOF), together with the results of the RSA, will be used to identify T cell signatures characteristic of distinct risk categories of LTBI. Certain of te validated T cell signatures will correspond to efficacious immune responses that are desirable targets of TB vaccine development, while others will be useful for identifying individuals with LTBI that are at highest risk of progression to active TB, so these individuals can be prioritized for preventive interventions. Our human studies will be conducted in Atlanta, GA, USA, and in collaboration with investigators at the Kenya Medical Research Institute/U.S. Centers for Disease Control (KEMRI/CDC); studies of TB in nonhuman primates will be done by experts at two national primate research centers (Yerkes and Tulane). The team we have assembled possesses a wide range of knowledge and expertise, and is poised to generate improved understanding of TB immunity to contribute to the elimination of TB.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Emory/Georgia TB Research Advancement Center (TRAC)
  • 批准号:
    10596169
  • 项目类别:
  • 资助金额:
    $21.88万
  • 财政年份:
    2022
  • 负责人:
    HENRY M BLUMBERG
  • 依托单位:
Emory/Georgia TB Research Advancement Center (TRAC)
  • 批准号:
    10429401
  • 项目类别:
  • 资助金额:
    $19.73万
  • 财政年份:
    2022
  • 负责人:
    HENRY M BLUMBERG
  • 依托单位:
Georgia CTSA Research Supplement to Promote Diversity in Health-Related Research (Hernandez)
  • 批准号:
    9815750
  • 项目类别:
  • 资助金额:
    $3.46万
  • 财政年份:
    2019
  • 负责人:
    HENRY M BLUMBERG
  • 依托单位:
J. NRSA Training Core
  • 批准号:
    10675159
  • 项目类别:
  • 资助金额:
    $87.97万
  • 财政年份:
    2017
  • 负责人:
    HENRY M BLUMBERG
  • 依托单位:
海外基金